Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 12.

Krzemieniecki, K; Sevelda, P; Erdkamp, F; Smakal, M; Schwenkglenks, Matthias; Puertas, J; Trojan, A; Szabo, Z; Bendall, K; Maenpaa, J (2014). Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy-findings from clinical practice. Supportive Care in Cancer, 22(3):667-677.

Renner, C; Zinzani, P L; Gressin, R; Klingbiel, D; Dietrich, P Y; Hitz, P; Bargetzi, M; Mingrone, W; Martinelli, G; Trojan, A; Bouabdallah, K; Lohri, A; Gyan, E; Biaggi, C; Cogliatti, S; Bertoni, F; Ghielmini, M; Brauchli, P; Ketterer, N (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97(7):1085-1091.

Trojan, A; Montemurro, M; Kamel, M; Kristiansen, G (2009). Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. Annals of Oncology, 20(11):1898-1899.

Bihl, F; Berger, C; Chisholm, J V; Henry, L M; Bertisch, B; Trojan, A; Nadal, D; Speck, R F; Flepp, M; Brander, C; Mueller, N J (2009). Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS, 23(14):1918-1922.

Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, Christian; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK. Annals of Oncology, 19(7):1288 -1292.

Trojan, A; Rajeswaran, R; Montemurro, M; Mütsch, Margot; Steffen, Robert (2007). Real time PCR for the assessment of CD8+ T cellular immune response after prophylactic vaccinia vaccination. Journal of Clinical Virology, 40(1):80-83.

Trojan, A; Tinguely, M; Vallet, S; Seifert, Burkhardt; Jenni, B; Zippelius, A; Witzens-Harig, M; Mechtersheimer, G; Ho, A; Goldschmidt, H; Jäger, D; Boccadoro, M; Ladetto, M (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Medical Weekly, 136(25-26):400-403.

Herr, D; Borelli, S; Kempf, W; Trojan, A (2005). Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin? Annals of Oncology, 16(3):515-516.

Trojan, A; Giger, R; Rist, N; Speck, R F (2004). Impaired CD8+ T-Cell Reactivity against Viral Antigens in Cancer Patients with Solid Tumors. Infection, 32(5):287-292.

Trojan, A (2003). Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Annals of Oncology, 14(3):501-502.

Trojan, A (2002). Fusion PET-CT imaging of neurolymphomatosis. Annals of Oncology, 13(5):802-805.

Hoerstrup, S P; Kadner, A; Melnitchouk, S; Trojan, A; Eid, K; Tracy, J; Sodian, R; Visjager, J F; Kolb, S A; Grünenfelder, J; Zund, G; Turina, M I (2002). Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation, 106(12 Sup):I143-I150.

This list was generated on Mon Jun 17 04:45:47 2019 CEST.